Lenvatinib

• Study of pembrolizumab, lenvatinib and chemotherapy combination in first line lung cancer Ended
  2024-511412-25-00 Phase II 1 country Fundacion GECP
• A clinical study of pembrolizumab with other study treatments in people with refractory lung cancer (MK-3475-B98) Ended
  2023-507687-38-00 Phase I/II 5 countries Merck Sharp & Dohme LLC
• A clinical study to compare Toripalimab (JS001) combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for… Ended
  2024-514207-34-00 Phase III 2 countries Shanghai Junshi Biosciences Co. Ltd.
• An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First-line Treatment in Participants with Advanced … Ended
  2022-502122-41-00 Phase III 14 countries Merck Sharp & Dohme LLC
• A Study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously … Ended
  2023-503229-21-00 Phase III 12 countries F. Hoffmann-La Roche AG
• Phase 3 Study of Belzutifan in Combination With Lenvatinib Versus Cabozantinib for Treatment of RCC Ended
  2024-510620-39-00 Phase III 13 countries Merck Sharp & Dohme LLC
• PEMbrolizumab Plus Lenvatinib In Second Line And Third Line Malignant Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA). Ended
  2024-516618-39-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in C… Ended
  2023-509604-15-00 Phase I (Other) 2 countries AstraZeneca AB
• A clinical study of different treatments for kidney cancer (MK-3475-03B) Ended
  2023-506839-15-00 Phase I/II 5 countries Merck Sharp & Dohme LLC
• Study to evaluate the safety and efficacy of nivolumab combined with ipilimumab as first-line (1L) therapy for participants with advanced HC… Ended
  2023-508635-31-00 Phase III 8 countries Bristol-Myers Squibb Services Unlimited Company
• Phase II multicentric study: efficacy evaluation of neo-adjuvant treatment associated with maintenance therapy by anti-PD1 immunotherapy on … Ended
  2024-513027-16-00 Phase II 1 country Institut Gustave Roussy
• Study of the benefit of lenvatinib treatment in waiting list of liver transplantation after TACE failure in patients with hepatocellular car… Ended
  2024-516408-40-00 Phase I/II 1 country Assistance Publique Hopitaux De Paris
• A Phase 2 Study of MK-4280A for the Treatment of Selected Solid Tumors Ended
  2023-505022-34-00 Phase II 4 countries Merck Sharp & Dohme LLC
• Comparative Bioavailability of Lenvatinib 10 mg Capsules in Healthy Subjects Ended
  2022-501327-25-00 1 country Bluepharma Industria Farmaceutica S.A.
• A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08 , an IL-15 Antibody Fusion Protein Targeting CTLA-4, Mo… Ended
  2024-511750-53-00 Phase I (FiH) 2 countries Salubris Biotherapeutics Inc.
• A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors Ended
  2023-505425-14-00 Phase I/II 1 country Eisai Limited
• SOLARIS – A phase-II open-label study of pembrolizumab and lenvatinib in patients with advanced stage hepatocellular carcinoma who are refra… Ended
  2024-515731-29-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
• Study of Avelumab in combination with Lenvatinib for children with primary CNS tumors Ended
  2024-512940-51-00 Phase I (Other) 2 countries Merck Healthcare KGaA
• 7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors Ended
  2023-505284-36-00 Phase II 6 countries Merck Sharp & Dohme LLC
• Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Solid Tumors Ended
  2023-503905-12-00 Phase II 4 countries Merck Sharp & Dohme LLC
• Phase 2 First-Line ES-SCLC Platform Study Ended
  2023-506538-56-00 Phase II 5 countries Merck Sharp & Dohme LLC
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal … Ended
  2022-501342-29-00 Phase III 6 countries Merck Sharp & Dohme LLC
• Phase 2 Study of MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular C… Ended
  2023-505698-34-00 Phase II 3 countries Merck Sharp & Dohme LLC
• Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain M… Ended
  2023-506315-17-00 Phase I/II 6 countries Merck Sharp & Dohme LLC

Showing 25–48 of 62 trials